Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06243757 · ClinicalTrials.gov registry record

A Study of Minimally Invasive Proximal Gastrectomy Versus Minimally Invasive Total Gastrectomy for Gastric and Gastroesophageal Junction Cancers

A clinical trial of Gastric Cancer and Gastroesophageal Junction Adenocarcinoma, sponsored by Memorial Sloan Kettering Cancer Center.

Active
Registry status
4
Enrollment target
8
Study locations

NCT06243757: Active study of Gastric Cancer and Gastroesophageal Junction Adenocarcinoma, sponsored by Memorial Sloan Kettering Cancer Center.

NCT06243757 is a study of Gastric Cancer and Gastroesophageal Junction Adenocarcinoma that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 4 participants, below the 319-participant average among 153 other Gastric Cancer trials with a reported enrollment target (99% lower). The trial reports 8 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06243757, a study of Gastric Cancer and Gastroesophageal Junction Adenocarcinoma, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.

ACTIVE NOT RECRUITING
Registry status
4 participants
Enrollment target
8
Study locations

Study Summary

Participants will a diagnosis of gastroesophageal junction (GEJ) adenocarcinoma and will have either a minimally invasive proximal gastrectomy (MIPG) or a minimally invasive total gastrectomy (MITG) as part of their routine care. Participants with complete a questionnaire 1 month before the surgical procedure and then 1, 3, 6 and 12 months after the surgical procedure.

Primary Outcome

The primary outcome is the appetite level score (with 0 being the best and 10 being the worst) according to the MDASi-GI at 3 months after surgery

Conditions Studied

Gastric Cancer Gastroesophageal Junction Adenocarcinoma GastroEsophageal Cancer

Interventions

  • OTHER MDASI-GI

Study Locations (8)

New York

  • Memorial Sloan Kettering Commack (All Protocol Activities) - Commack
  • Memorial Sloan Kettering Westchester (All Protocol Activities) - Harrison
  • Memorial Sloan Kettering Cancer Center (All Protocol Activities) - New York
  • Memorial Sloan Kettering Nassau (Limited Protocol Activites) - Rockville Centre

New Jersey

  • Memorial Sloan Kettering Basking Ridge (All Protocol Activities) - Basking Ridge
  • Memorial Sloan Kettering Monmouth (All Protocol Activities) - Middletown
  • Memorial Sloan Kettering Bergen (All protocol activities) - Montvale

Texas

  • MD Anderson Cancer Center (Data Analysis Only) - Houston

Trial Details

FieldValue
Enrollment Target 4 participants
Start Date 2024-01-08
Est. Completion 2036-01-08
Memorial Sloan Kettering Cancer Center

1,884 total trials

What the registry record for NCT06243757 still lists

NCT06243757 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 319-participant average among 153 other Gastric Cancer trials with a reported enrollment target (99% lower).

The record links to 3 conditions, with Gastric Cancer appearing as the primary indexed condition, and to 1 intervention - of which MDASI-GI is the first listed.

NCT06243757 lists 8 locations in 3 states (New York, New Jersey, Texas).

Frequently Asked Questions

What is clinical trial NCT06243757 about?

NCT06243757 is a clinical study titled "A Study of Minimally Invasive Proximal Gastrectomy Versus Minimally Invasive Total Gastrectomy for Gastric and Gastroesophageal Junction Cancers". Participants will a diagnosis of gastroesophageal junction (GEJ) adenocarcinoma and will have either a minimally invasive proximal gastrectomy (MIPG) or a minimally invasive total gastrectomy (MITG) as part of their routine care. Participants with complete a questionnaire 1 month before the surgical...

What is the current status of trial NCT06243757?

This trial is currently active not recruiting. The enrollment target is 4 participants. The study started on 2024-01-08. Estimated completion is 2036-01-08.

What conditions does trial NCT06243757 study?

This clinical trial studies the following conditions: Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, GastroEsophageal Cancer.

What interventions are being tested in trial NCT06243757?

The interventions under investigation include: MDASI-GI (OTHER).

Who is sponsoring clinical trial NCT06243757?

This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06243757 being conducted?

This trial has 8 study locations across New Jersey, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Gastric Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06243757's enrollment target sits among peer trials

4 154th of 153 the lowest of 153 other Gastric Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Gastric Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT06243757, the US trial registry maintained by the National Library of Medicine. NCT06243757 (small enrollment · multi site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.